MegaPro Biomedical Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. Current Progress of Product Development
2. MPB-1514
3. MPB-1523 (IOP Injection)
4. MPB-1734: A New Formulation Anti-cancer Drug
2. MPB-1514
3. MPB-1523 (IOP Injection)
4. MPB-1734: A New Formulation Anti-cancer Drug
The content above was translated by Ai
Founded Year
2014
Unified Business No.
24765568
Status
Active
Number of Employees
0
Total Paid-in
Capital
792,935,030 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Emerging Stock Exchange(2021)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
MegaPro Biomedical is a clinical-stage nanomedicine company leveraging its proprietary Nano-Particle Platform (PEGylated iron oxide nanoparticles) across diagnostics, cell therapy, and anemia treatment. Key programs include MPB-1523 (liver cancer, Phase III) and MPB-2354 ("Visible Cell Therapy" for Critical Limb Ischemia), targeting global expansion through strategic licensing.
The content above was translated by Ai
